{
    "Trade/Device Name(s)": [
        "EliATM CCP",
        "EliATM CCP Control"
    ],
    "Submitter Information": "Phadia AB",
    "510(k) Number": "K061165",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NHX"
    ],
    "Summary Letter Date": "April 25, 2006",
    "Summary Letter Received Date": "April 26, 2006",
    "Submission Date": "April 13, 2006",
    "Regulation Number(s)": [
        "21 CFR 866.5775"
    ],
    "Regulation Name(s)": [
        "Rheumatoid Factor Immunological Test System"
    ],
    "Analyte Class(es)": [
        "immunology",
        "autoimmune"
    ],
    "Analyte(s)": [
        "IgG antibodies to cyclic citrullinated peptides (CCP)",
        "Anti-CCP antibodies"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "ImmunoCAP 100",
        "ImmunoCAP 250"
    ],
    "Method(s)/Technology(ies)": [
        "Fluorescence immunoassay (FIA)",
        "EliA IgG method"
    ],
    "Methodologies": [
        "Immunoassay",
        "Non-competitive solid phase EIA"
    ],
    "Submission Type(s)": [
        "Assay",
        "Control",
        "Reagent",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for EliATM CCP and EliATM CCP Control fluorescent immunoassay for anti-CCP IgG detection on ImmunoCAP instruments for rheumatoid arthritis diagnosis support",
    "Indications for Use Summary": "EliA CCP measures IgG antibodies to CCP in human serum and plasma to aid in diagnosing rheumatoid arthritis; EliA CCP Control monitors performance of anti-CCP antibody measurement with ImmunoCAP using EliA IgG method",
    "fda_folder": "Immunology"
}